According to the report titled ‘Global Cyclooxygenase2 inhibitor Market Size study, by Indication (Osteoarthritis, Rheumatoid arthritis and Others), Types (Selective cox 2 inhibitor and Non-selective cox 2 inhibitor), Route of Administration (Oral, parenteral and Others), End-Users (Hospitals, Specialty Clinics, Others), Distribution Channel (Hospital Pharmacy, Retail Pharmacy, Others) and Regional Forecasts 2020-2026’, available with Market Study Report, global cyclooxygenase2 inhibitor market is anticipated to record substantial growth during 2020-2026.
 

Rising pervasiveness of chronic diseases like rheumatoid arthritis is likely to boost the demand for painkillers, hence propelling global cyclooxygenase2 inhibitor market expansion. As per trusted estimates, rheumatoid arthritis affected over 1.3 million Americans in the year 2018 and as many as 1% of worldwide population.
 

Notably, COX-2 or cyclooxygenase2 inhibitor, a nonsteroidal anti-inflammatory drug, is utilized to reduce inflammation and pain. It is being examined as an anticancer drug and colon polyps. Rising cognizance of health condition, and increasing adoption of COX-2 inhibitors like painkillers are driving the growth of global cyclooxygenase2 inhibitor market.
 

Request sample copy of this Report: https://www.marketstudyreport.com/request-a-sample/2683165/
 

Safety problems and serious side effects of COX-2 inhibitors can, however, may hold back the growth of the industry.
 

Based on indication, global cyclooxygenase2 inhibitor market is divided into rheumatoid arthritis, osteoarthritis, and others. Speaking of type, the industry is bifurcated into non-selective COX-2 inhibitor, and selective COX-2 inhibitor. In terms of route of administration, the market is split into parental, oral, and others. Elaborating on end-user scope, worldwide cyclooxygenase2 inhibitor industry is categorized into specialty clinics, hospitals, and others. While the distribution channels include retail pharmacy, hospital pharmacy, and others.
 

Citing the regional landscape, worldwide cyclooxygenase2 inhibitor market sphere is segmented into North America, Europe, Latin America, Asia Pacific, and Rest of the World. The report cites that Asia Pacific currently holds significant market share and is expected to grow further over the assessment period. The regional growth is credited to high pervasiveness of chronic disease and rising cognizance of its diagnosis.
 

Meanwhile, North America cyclooxygenase2 inhibitor industry is expected to register decent growth over the estimated timeframe, owing to presence of major players focusing on emerging technologies in the region.
 

Major contenders influencing global cyclooxygenase2 inhibitor market dynamics are Torrent Pharmaceuticals Ltd., Cipla Inc., Aurobindo Pharma, Alembic Pharmaceuticals Limited, Teva Pharmaceutical Industries Ltd., Mylan N.V., Cadila Pharmaceuticals Limited, Sabinsa Corporation, Novartis AG, Bayer AG, and Pfizer Inc.